Navigation Links
Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
Date:4/26/2011

ing conventional dosing of paclitaxel at 200 mg/m2 every three weeks (conventional treatment Arm A) with paclitaxel blood level testing and subsequent individual dose adjustments (experimental treatment Arm B), with the primary objective to significantly reduce grade 4 neutropenia in patients within treatment Arm B, without adversely affecting chemotherapy efficacy in terms of progression-free survival (PFS) and overall survival (OS).

About non-small cell lung cancer (NSCLC)

Lung cancer is the most common cancer in the world today, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases.  According to the Centers for Disease Control and Prevention (CDC), about 90% of lung cancer deaths in men and almost 80% of lung cancer deaths in women are due to smoking.  Treatment for NSCLC varies depending on the stage of the cancer, though combinations of taxanes are routinely used as part of first-line therapy treatment regimens.  Common side effects of taxanes include polyneuropathy and bone marrow suppression which results in severe neutropenia.

About pharmacokinetic-guided dosing

There is increasing evidence for the relationship between paclitaxel plasma concentrations, drug-associated toxicity, especially neutropenia and clinical outcome.  These data are derived from various pharmacological studies in patients with solid tumors, including lung cancer, ovarian cancer, breast cancer and less frequent cancer types.  The aim of TDM is to decrease toxicity while maintaining or improving treatment efficacy as compared to the standard of care.  Prospective pharmacokinetic studies with dose adjustments are important to evaluate the value of paclitaxel TDM.

About the CESAR Central European Society for Anticancer Drug Research-EWIV  

In the context of the pan-European Early Drug Development Network, CESAR represents the Central European platform for n
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Symmetry Medical Centralizes Businesses Under CEO
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. FDA Approves Gadavist for Central Nervous System Scans
4. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
8. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
11. Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   InnFocus, Inc ., reported ... the United States for up to 3 years ... Summit in Chicago . The ... of the annual meeting of the American Academy of ... treated approximately 150 glaucoma patients in 6 countries by early ...
(Date:10/17/2014)... , Oct. 17, 2014  China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... the Company has received approval from the China ... manufacturing of human prothrombin complex concentrate ("PCC") at ... Taibang,s new coagulation factor production facility for Good ...
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
Breaking Medicine Technology:InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... May 10, 2011 Cardica, Inc. (Nasdaq: CRDC ... and nine months ended March 31, 2011. Cardica,s management will ... to discuss the financial results and provide an update on ... diligently to bring our first anticipated commercial microcutter device, the ...
... 10, 2011 Cobalis Corp. (CLSC.PK) announced today they ... Allergy Defense Formula , on major national cable and ... featuring leading US allergist Dr. Paul H. Ratner, MD, ... allergies, giving seasonal and year-round sufferers the first truly ...
Cached Medicine Technology:Cardica Announces Fiscal 2011 Third Quarter Financial Results 2Cardica Announces Fiscal 2011 Third Quarter Financial Results 3Cardica Announces Fiscal 2011 Third Quarter Financial Results 4Cardica Announces Fiscal 2011 Third Quarter Financial Results 5Cardica Announces Fiscal 2011 Third Quarter Financial Results 6Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 2Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 3
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Sam Smith as the new Chief Executive Officer of the international ... the International Board of Directors on Tuesday. , ... ... the unanimous confirmation of Sam Smith as the new Chief Executive ...
... Healthcare IT provider grows its operations in the Middle East , ... Systems Corporation (NYSE: PER ) ( www.perotsystems.com ) today ... to manage the pilot deployment of VistA - an open source ... a clinic in the capital, Amman. , ...
... EMPHYSEMA AT RISK FOR OSTEOPOROSIS , New research shows ... includes emphysema and chronic bronchitis, may also be at ... scans and pulmonary function tests on 65 male patients ... compare vertebral bone density with percentage of low attenuation ...
... D. England, MD, Professor and Chairman of Neurology at ... is the principal investigator of two studies recommending ... nerve disorder that to this time had few evidence-based ... two separate papers in the December 3, 2008 online ...
... The American Society of Hematology (ASH) will host its ... Marriott on Thursday, December 4, 2008, beginning at 8:00 ... hematology, the biological sciences, and medical research, is held ... year, students will have the opportunity to explore research ...
... N.J., Dec. 3 MedQuist Inc. (Nasdaq: MEDQ ... world, is pleased to announce the positive resolution of several ... Resolution of the DOJ Investigation , ... an administrative HIPAA subpoena for documents from the United States ...
Cached Medicine News:Health News:New CEO Takes Helm at Mercy Ships 2Health News:New CEO Takes Helm at Mercy Ships 3Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 2Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 3Health News:Journal CHEST: December highlighted studies 2Health News:LSUHSC's England leads development of new testing guidelines for common nerve disorder 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6
... oximeters available, Datex-Ohmeda s TuffSat is the ... transport, and EMS. TuffSat comes fully loaded ... index measurement) a quick, easy-to-use clinical ... perfusion at the sensor site. Now you ...
... A tool for Clinical Professionals and Researchers., ... an easy and efficient way to collect data ... minutes to days at selectable time intervals. With ... straight from the monitor via an interface cable ...
... care challenge., ,The S/5 Critical Care Monitor ... solution for the varying needs of critical care. ... of parameter module options, display and mounting options, ... optimize the bedside set-up to help meet your ...
... modular, easy to use., ,The S/5 ... small-footprint monitor ideally suited for medium care ... modules and Datex-Ohmeda supplies and accessories., ... the same user interface and features as ...
Medicine Products: